摘要
Abstract
Objective To investigate the efficacy and adverse reactions of oxaliplatin (L-OHP) combined with docetaxel (DOC) chemo-therapy in the treatment of advanced esophageal cancer. Methods 82 patients with advanced esophageal cancer in our hospital were selected in this study. All patients were randomly divided into two groups. The observation group (n=41) had chemotherapy with DOC plus L-OHP and the control group (n=41) with DOC plus cisplatin(DDP). The short-term curative effects, survival and adverse reactions were compared between the two groups. Results The objective efficiency was 53.66%in observation group and 43.90%in control group, without statistically significant difference between the two groups (P>0.05). The median survival time (MST) and the median time to progression (TTP) in the ob-servation group were respectively (9.25±2.52) months and (6.42±1.21) months, and were respectively (8.62±2.35) months and (5.95±1.17) months in the control group. There were also no statistical differences between the two groups (P>0.05). However, in the observation group, the clinical benefit was respectively 41.46%, 65.85%and 24.39%for analgesic reduced dose more than or equal to 50%, an improvement in KPS more than or equal to 20 points, and those weight gain more than or equal to 7%, all significantly higher than those of the control group of 19.51%, 43.90%and 7.32%(P<0.05). The incidence rate of leukopenia, thrombocytopenia, nausea&vomiting, and diarrhea was 39.02%, 7.32%, 29.27%and 4.88%in observation group, all significantly lower than that in the control group of 73.17%, 29.27%, 78.05%and 24.39%respectively (P<0.05). Yet the observation group had significantly higher occurrence rate of nervous system toxicity than that of the control group (60.98%vs.14.63%) (P<0.05). Conclusion DOC combined with L-OHP was effective in the treatment of ad-vanced esophageal cancer, and adverse reactions could be tolerated Therefore, the chemotherapy of DOC plus L-OHP could be popularly applied in clinic.关键词
食管癌/晚期/奥沙利铂/顺铂/多西他赛/临床疗效/不良反应Key words
Esophageal cancer/Advanced/Asha Leigh Per/Cisplatin/Docetaxel/Clinical efficacy/Adverse reaction分类
医药卫生
